阿托伐他汀可减轻唑来膦酸诱导的大鼠颌骨坏死。 - Suppr | 超能文献

Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.

作者信息

Pazianas Michael

机构信息

Institute of Musculoskeletal Sciences, Oxford University, Oxford OX3 7LD, UK.

出版信息

Bone. 2022 Dec;165:116561. doi: 10.1016/j.bone.2022.116561. Epub 2022 Sep 20.

DOI:10.1016/j.bone.2022.116561

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.阿托伐他汀可减轻唑来膦酸诱导的大鼠颌骨坏死。

Bone. 2022 Dec;165:116561. doi: 10.1016/j.bone.2022.116561. Epub 2022 Sep 20.

2

Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.阿托伐他汀可减轻唑来膦酸诱导的大鼠颌骨坏死。

Bone. 2022 Nov;164:116523. doi: 10.1016/j.bone.2022.116523. Epub 2022 Aug 17.

3

Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.双膦酸盐类药物所致颌骨坏死：综述、临床意义及病例报告

Head Neck Pathol. 2007 Dec;1(2):156-64. doi: 10.1007/s12105-007-0022-5. Epub 2007 Dec 8.

4

Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis.双膦酸盐类药物的最新进展以及双膦酸盐类药物所致颌骨坏死的潜在病理生物学机制

Oral Dis. 2008 Apr;14(3):277-85. doi: 10.1111/j.1601-0825.2007.01381.x.

5

Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.癌症患者接受地舒单抗或唑来膦酸治疗后的颌骨坏死：丹麦、挪威和瑞典监管机构授权后队列安全性研究结果。

Cancer. 2021 Nov 1;127(21):4050-4058. doi: 10.1002/cncr.33802. Epub 2021 Jul 26.

6

[Medication-related osteonecrosis of the jaws associated with the use of bone-modifying agents].与骨改良剂使用相关的颌骨药物性骨坏死

Stomatologiia (Mosk). 2024;103(1):59-62. doi: 10.17116/stomat202410301159.

7

Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.唑来膦酸相关性颌骨坏死。大鼠拔牙实验模型。

J Craniomaxillofac Surg. 2014 Sep;42(6):744-50. doi: 10.1016/j.jcms.2013.11.005. Epub 2013 Nov 15.

8

Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.骨转移患者使用破骨细胞抑制剂后颌骨坏死的发生率：一项回顾性队列研究。

Cir Cir. 2019;87(4):396-401. doi: 10.24875/CIRU.18000661.

9

Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.抗癌药物唑来膦酸相关性颌骨坏死的药物治疗预后。

J Formos Med Assoc. 2021 Aug;120(8):1572-1580. doi: 10.1016/j.jfma.2020.11.017. Epub 2020 Dec 11.

10

[Avascular osteonecrosis of the jaws induced by diphosphonates].双膦酸盐所致颌骨无血管性骨坏死

Therapie. 2006 Jul-Aug;61(4):363-5. doi: 10.2515/therapie:2006061.

引用本文的文献

1

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy.病例报告：单剂量低剂量地诺单抗引发双膦酸盐治疗后骨质疏松症患者发生下颌骨坏死性骨炎。

Front Oral Health. 2024 Dec 4;5:1473049. doi: 10.3389/froh.2024.1473049. eCollection 2024.

2

A novel shockwave-driven nanomotor composite microneedle transdermal delivery system for the localized treatment of osteoporosis: a basic science study.一种用于骨质疏松症局部治疗的新型冲击波驱动纳米马达复合微针经皮给药系统：一项基础科学研究。

Int J Surg. 2024 Oct 1;110(10):6243-6256. doi: 10.1097/JS9.0000000000001280.